m+Medelevator.RU
← Поиск публикаций
Innovation (Cambridge (Mass.)) · 2025

International guidelines on the diagnosis and treatment of NUT carcinoma.

СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Zhang Yu, Zhang Qi, Hao Yue, Luo Jia, Piao Yingshi, Wang Wenxian, Song Zhengbo, Li Ziming, Brcic Luka, Liu Aijun, Yu Jinpu, Tsutani Yasuhiro, Zhong Wenzhao, Fang Wenfeng, Wang Zhijie, Ren Shengxiang, Papavassiliou Athanasios G, Zhang Yongchang, Liu Jingjing, Zhang Shirong, Cai Xiuyu, Cangir Ayten Kayi, Liu Anwen, Li Wen, Lococo Filippo, Zhan Ping, Liu Hongbing, Lv Tangfeng, Miao Liyun, Min Lingfeng, Popper Helmut, Chen Yu, Yuan Jingping, Wang Feng, Jiang Zhansheng, Lin Gen, Huang Long, Pu Xingxiang, Lin Rongbo, Kairemo Kalevi, Liu Weifeng, Rao Chuangzhou, Lv Dongqing, Yu Zongyang, Leanne Ashrafian, Li Xiaoyan, Tang Chuanhao, Siddique Hifzur R, Zhou Chengzhi, Zhang Junping, Xue Junli, Shelat Vishal, Guo Hui, Chu Qian, Meng Rui, Ardeshir Fatemeh, Wu Jingxun, Zhang Rui, Zhou Jin, Kratzke Robert A, Zhu Zhengfei, Li Yongheng, Qiu Hong, Xia Fan, Calabrese Fiorella, Xia Yang, Mariani Alessandro Wasum, Lu Yuanyuan, Chen Xiaofeng, Klein Mark A, Ge Rui, Dai Enyong, Schönthal Axel H, Han Yu, Guo Zhenying, Zhang Jian, Ji Yinghua, Liang Xianbin, Zhang Hongmei, Ma Xuelei, Chiappetta Marco, Liu Xuewen, Salle Francoise Galateau, Yao Yu, Szolkowska Malgorzata, Pan Weiwei, Pang Fei, Wu Fan, Watzka Stefan B, Wang Liping, Zhu Youcai, Lin Li, Sharma Aparna, Tu Jianfei, Lin Xinqing, Cai Jing, Xu Ling, Li Jisheng, Jiao Xiaodong, Li Kainan, Zauderer Marjorie G, Wei Jia, Feng Huijing, Wang Lin, Du Yingying, Yao Wang, Dudnik Elizabeth, Shi Xuefei, Niu Xiaomin, Yuan Dongmei, Yao Yanwen, Huang Jianhui, Feng Yue, Zhang Yinbin, Song Binbin, Li Wenfeng, Fu Jianfei, Baine Marina K, Sun Pingli, Wang Hong, Ye Mingxiang, Wang Dong, Wang Zhaofeng, Wu Jing, Yang Yunyun, Fang Yuan, Wang Zhen, Wan Bin, Lv Donglai, Chen Huafei, Yang Shengjie, Kang Jing, Zhang Jiatao, Zhang Chao, Shi Lin, Wang Yina, Sobeih Mohamed Emam, Li Bihui, Lian Bin, Mao Lili, Zhang Zhang, Wang Ke, Li Zhongwu, Liu Zhefeng, Yang Nong, Wu Lin, Chen Xiaobing, Jin Gu, Li Miao, Wang Guansong, Marron Thomas U, Wang Jiandong, Popat Sanjay, Fang Meiyu, Fang Yong, Mansilla Daniel, Li Yuan, Wang Xiaojia, Chen Jing, Zhang Yiping, Zhu Xixu, Shen Yi, Ma Shenglin, Mansfield Aaron S, Wang Biyun, Si Lu, Roden Anja C, Grønberg Bjørn H, Song Yong, Shapiro Geoffrey I, French Christopher A, Lu Yuanzhi, Wang Qian, Xu Chunwei

Аннотация

Nuclear protein in testis (NUT) carcinoma (NC) represents a rare, clinically aggressive cancer defined by pathognomonic NUT Midline Carcinoma Family Member 1 (NUTM1) gene fusions, with bromodomain and extraterminal domain (BET) protein 4 (BRD4)-NUTM1 being the predominant oncogenic driver. Since its description in 1991, gradual advances have clarified the pathologic mechanisms of NC and its diagnostic methods; however, NC treatment remains a significant challenge. Moreover, diagnostic and treatment approaches for this cancer require further validation and standardization. These guidelines were developed by the Chinese Alliance of Research for NC (ChARN) based on current evidence in the literature and incorporate consensus-based input from multiple international experts. They provide comprehensive guidance on NC diagnosis and treatment, covering epidemiology, pathogenesis, diagnostic methods, therapeutic strategies, BET-inhibitor toxicity, palliative care, and prognostic assessment during follow-up. They also emphasize the importance of multidisciplinary team collaboration in NC treatment and recommend prioritizing enrollment in prospective clinical trials for patients. Current mainstays of treatment include surgical resection, radiotherapy, and medical treatment (chemotherapy, targeted therapy, and immunotherapy), although no standard treatment protocol exists. Future research directions include improving diagnostic efficiency, exploring new therapeutic strategies (such as highly selective BET inhibitors, BET-inhibitor combinations, and PROTAC technologies), and recommending basket trials as a research approach for patients with NUTM1 gene fusions.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты